What to Expect in VTE Devices, Trials, and More: An Interview with Oren A. Friedman, MD
By DocWire News Editors - Last Updated: September 6, 2023DocWire News chats with Oren A. Friedman, MD, an associate professor of medicine, Cedars-Sinai Medical Center, and director of the Intensive Care Unit, Marina Del Rey Hospital in Los Angeles, about the latest developments in venous thromboembolism. Dr. Friedman touches on new trials, new technologies, and also on the ways that the COVID-19 pandemic has impacted care delivery for his patients.
Advertisement
To read more about VTE, visit our VTE Knowledge Hub.
To watch more videos with key opinion leaders, visit our YouTube channel.
Follow us on Twitter (@mydocwire) and Facebook (@mydocwire).
Advertisement
Related Posts
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.